London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Being serious this time (!) the 16th is correct.
Should it have read 18th? Great - a new question for a thread! I'll say 19th.
Did they get the date right on this this statement?
"It is expected that Open Orphan ordinary shares will be marked "ex rights" at 8.00 a.m. on 16 June 2020"
Shout it have read the 18th??
Pre it is.
In the future
Soon
one day...
Sometime
Now
Pre
Post
Question: Sequencing of results news v spin off news. Both due in days/weeks. Do we think the spin off news comes pre or post results?
Squirrel, Yes, that's why i called it consultancy...as i remember he said something along the lines of "we could hold their hands" as in not do the trial themselves. I also seem to remember by the way CF talked that it was more than one! but i would have to go back and listen again to be sure. My understanding, from memory was that it would be an ongoing situation from one Chinse trial to the next trial, OO as consultants...for a charge!
vascular, I’ve just listened to the Investor Meet interview again. My take on the China £30/£50 millions was that is for Orphan to train the Chinese to do a study themselves. He went on to say this wouldn't be a problem as only the Chinese pharmas would want to use a Chinese study. The rest of the western world would use OOrphan
I am not sure if the potential of the consultancy work has ben taken seriously ( as CF stated in recent presentation if the Chinese are happy to pay $30 -£$0 million a trial ( we can hold their hand through out the entire process). This would be another very valuable revenue stream and i guess would not just apply to the Chinese. Its a reality, being discussed and provides a solution to the world governments / pharma's biggest problems at this time, so as likely to go ahead,as not imo.
Gift horse's mouths comes to mind when I read these kind of posts.
Maybe hold off ordering the Porches just yet guys. lol
I'll happy knowing that my holdings value maybe somewhere North of here if I keep holding. :)
To be honest, I have a feeling he has probably stated both over the many interviews, but it was actually reported here, by a third party.
"In a media interview today, Open Orphan’s CEO, Cathal Friel, said that its valuation could surpass $1 billion soon given the huge interest that the challenge study has attracted from major pharmaceutical companies."
https://www.asktraders.com/analysis/open-orphan-shares-rally-7-on-ethics-approval-of-covid-19-human-challenge-trial/
Don't get too excited, I can't remember which interview it was but he said £1 billion taking spin offs into account. Who knows how well they are going to take off though, could be a lot more...
My understanding is that over the longer-term OO will become a $1 billion business, trading as it does today.
Short term, the 4 /5 SPACS will be rolled out, and one in particular SPAC ( DiM) has the potential to be larger than OO !
He recently stated that all Spacs will be spun out before year end 21 .....ok, maybe first quarter next year with slippage.
Therefore, using his forecasts all the SPACs will be history early next year...and OO will continue to grow substantially over the longer term, say two years into a £B company.
So my understanding is the SPACS are a ( very welcome) side show, to his longer term plans for OO.
Thats my understanding that Orph will be worth 1Bn on its own. The spin offs are in addition.
He answers it all here, worth listening to again . https://www.youtube.com/watch?v=IrP4w9athkg
Guygad, I didn't suggest you were nervous, I asked what you meant by asking others if they were nervous. It seems your reason for anxiety is to do with the results not being published yet. No, I don't think anyone is "nervous" about that, as we wouldn't expect them to be published until later in the month.
BlahBlahDoh... not nervous, or not very nervous, otherwise i would have sold down to zero. (I sliced my holdings a month ago so I'm long since in profit in the name regardless of what happens.) It's more a question of capital maintenance that any investor should ask of all of their holdings. ORPH is a £241m market cap that has performed astonishingly well and has excellent prospects for the future but we've not seen anything in terms of numbers for 9 months.
He has decent revenue kicking in now. Most likely revenue may get split. I would imagine bulk realised for after results as better to realise it this year so we get one bumper increase.
Han**** at the Select Committee commenting that he is dealing with monkey virus and other outbreaks. Then mentioning that Government is concentrating in these areas to safeguard our future. Looks that our services are more than appreciated.
Government and OO working very tightly. Government in post Brexit Britain really seeing pharma services and biotech as key growth market. This is an area where both can win.
I'm still expecting a FY20 loss of -£5m or -£6m on 21st June, anything else would be a massive shock considering we reckon CF is likely to put larger contracts towards FY21 for accounting to show a decent profit.